Visual acuity development after anti-vegf therapy in diabetic macular edema
Introduction: Diabetic macular edema is the most frequent cause of decreased visual acuity in diabetics. The therapy most used in this pathology is antiangiogenic therapy. Objective: Identify visual acuity modification in patients with macular edema due to diabetic retinopathy after antiangiogenic t...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | México |
| Institución: | UNIVERSIDAD AUTÓNOMA DE AGUASCALIENTES |
| Repositorio: | Luxmédica |
| Idioma: | español |
| OAI Identifier: | oai:revistas.uaa.mx:article/4618 |
| Acceso en línea: | https://revistas.uaa.mx/index.php/luxmedica/article/view/4618 |
| Access Level: | acceso abierto |
| Palabra clave: | Retinopatía diabética Edema macular Diabetes Mellitus Diabetic Retinopathy Macular Edema |
| Sumario: | Introduction: Diabetic macular edema is the most frequent cause of decreased visual acuity in diabetics. The therapy most used in this pathology is antiangiogenic therapy. Objective: Identify visual acuity modification in patients with macular edema due to diabetic retinopathy after antiangiogenic therapy. Material and methods: An observational, retrospective, non-randomized case study was carried out, convenience sampling, in a population of patients with macular edema due to diabetic retinopathy, a total of 304 medical charts were reviewed, by single blind and two different researchers. A total of 189 files where selected, including only those that had all the approvals according to the inclusion parameters during the period from January 2022 to November 2022. Results: 26 men and 19 women, 60 eyes considered (29 right and 31 left) presenting macular edema due to diabetic retinopathy under treatment with antiangiogenic therapy with Aflibercept, it was found that the lower macular thickness is, the better visual acuity (r=0.73), (p<0.001). Visual acuity changes went, on average, from 0.16 baseline to a result of 0.36, indicating that there is in average a 30% improvement in final visual acuity. Conclusion: Intravitreal injection with Aflibercept as a treatment for macular edema due to diabetic retinopathy shows an improvement in visual acuity by reducing macular thickness. Fecha de recepción: 23/08/2023 Aceptación de originales: 13/09/2023 |
|---|